Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Gleevec is the brand name for imatinib, a targeted cancer medicine taken by mouth. It blocks certain abnormal proteins that help cancer cells grow. Its uses include specific leukemias, gastrointestinal stromal tumors, and other conditions defined in its prescribing information.
read more about gleevec ...Gleevec treats Philadelphia chromosome-positive chronic myeloid leukemia in eligible adults and children. It is also used for certain gastrointestinal stromal tumors, including treatment after surgery in eligible adults. Other labeled uses depend on the disease type and its genetic or protein markers.
Imatinib blocks enzymes called tyrosine kinases. These include the abnormal BCR-ABL protein involved in Philadelphia chromosome-positive leukemia and the KIT protein involved in certain gastrointestinal stromal tumors. Blocking those signals can slow cancer cell growth.
Gleevec tablets are taken with a meal and a large glass of water. The dose and number of daily doses depend on the condition being treated. The oncology team checks blood counts and liver function and adjusts treatment when needed.
Swelling, nausea, diarrhea, muscle cramps, rash, and fatigue can occur. Gleevec can also cause low blood cell counts, liver injury, or significant fluid retention. Report rapid weight gain, unusual bleeding, or yellowing of the skin or eyes to the care team.
Gleevec is a targeted cancer medicine called a tyrosine kinase inhibitor. It blocks specific growth signals in susceptible cancer cells.
Yes. Take it with a meal and a large glass of water as directed.
No. Its labeled uses include tumors with specific features, such as KIT positivity. Testing and the treatment setting guide the decision.
Gleevec can lower blood cell counts and affect the liver. Tests help the care team monitor for these effects.
GLEEVEC (imatinib mesylate) tablets: Prescribing Information. Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/gleevec_tabs.pdf. Date Accessed October 6, 2026.
GLEEVEC- imatinib mesylate tablet. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b. Date Accessed October 6, 2026.
Imatinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a606018.html. Date Accessed October 6, 2026.
Imatinib (oral route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/imatinib-oral-route/description/drg-20068331. Date Accessed October 6, 2026.
Imatinib Mesylate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate. Date Accessed October 6, 2026.